Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
GVHD Indication Strategy Report 2026: JAK1, ROCK2, Trials and Deals
20 July 2026
GVHD Indication Strategy Report 2026: JAK1, ROCK2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Primary Sclerosing Cholangitis Indication Strategy Report 2026: FXR, CCR2, Trials and Deal Outlook
20 July 2026
Primary Sclerosing Cholangitis Indication Strategy Report 2026: FXR, CCR2, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Primary Biliary Cholangitis Indication Strategy Report 2026: PPARδ, FXR, Trials and Deals
20 July 2026
Primary Biliary Cholangitis Indication Strategy Report 2026: PPARδ, FXR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Autoimmune Hepatitis Indication Strategy Report 2026: CD20, IL-6, Trials and Deals
20 July 2026
Autoimmune Hepatitis Indication Strategy Report 2026: CD20, IL-6, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Pemphigus Vulgaris Indication Strategy Report 2026: CD20, FcRn, Trials and Deal Outlook
20 July 2026
Pemphigus Vulgaris Indication Strategy Report 2026: CD20, FcRn, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Bullous Pemphigoid Indication Strategy Report 2026: FcRn, IL-4Rα, Trials and Deal Outlook
20 July 2026
Bullous Pemphigoid Indication Strategy Report 2026: FcRn, IL-4Rα, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Inclusion Body Myositis Indication Strategy Report 2026: MSTN, TGF-β, Trials and Deal Outlook
20 July 2026
Inclusion Body Myositis Indication Strategy Report 2026: MSTN, TGF-β, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Polymyositis Indication Strategy Report 2026: IFNAR1, JAK1, Trials and Deal Outlook
20 July 2026
Polymyositis Indication Strategy Report 2026: IFNAR1, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Dermatomyositis Indication Strategy Report 2026: IFNAR1, JAK1, Trials and Deal Outlook
20 July 2026
Dermatomyositis Indication Strategy Report 2026: IFNAR1, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Axial Spondyloarthritis Indication Strategy Report 2026: IL-17A, TNF, Trials and Deal Outlook
20 July 2026
Axial Spondyloarthritis Indication Strategy Report 2026: IL-17A, TNF, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Polymyalgia Rheumatica Indication Strategy Report 2026: IL-6, JAK1, Trials and Deal Outlook
20 July 2026
Polymyalgia Rheumatica Indication Strategy Report 2026: IL-6, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Giant Cell Arteritis Indication Strategy Report 2026: IL-6, JAK1, Trials and Deals
20 July 2026
Giant Cell Arteritis Indication Strategy Report 2026: IL-6, JAK1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.